Clinical trial · Observational
Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
NCT05669105CI-TRIAL-00071616unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Specimen sample | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Biospecimen & Clinical Data Collection
- timeFrame
- 10 years
- description
- The primary objective is to collect 2000 whole blood samples from subjects who are diagnosed with active lung cancer. The purpose of this study is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations can analyze how the immune response can take place, and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Participants willing and able to provide written informed consent * Participants are willing and able to provide appropriate photo identification * Participant's age 18 - 100 years old * Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.) * Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records Exclusion Criteria: * Participants who are pregnant or nursing * Participants with a known history of HIV, hepatitis, or other infectious diseases * Participants who have taken an investigational product in the last 30 days * Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months * Participants currently enrolled in a clinical trial * Participants currently in remission
References
Publications (0)
Data not yet available
No reference posted for this study.